Methylseleninic acid (MSA) inhibits 17β-estradiol-induced cell growth in breast cancer T47D cells via enhancement of the antioxidative thioredoxin/ thioredoxin reductase system

Biomedical Research (Japan)

Volumn 33, Issue 4, 2012, Pages 201-210

  Okuno, Tomofumi ^a   Miura, Kiyoshi ^a   Sakazaki, Fumitoshi ^b   Nakamuro, Katsuhiko ^a   Ueno, Hitoshi ^a  

^a SETSUNAN UNIVERSITY   (Japan)

^b OSAKA OHTANI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; METHYLSELENINIC ACID; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER LOCALIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; ESTROGEN RESPONSIVE FINGER PROTEIN GENE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; ONCOGENE; OXIDATIVE STRESS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ENZYME ACTIVATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE PEROXIDASE; HUMANS; ORGANOSELENIUM COMPOUNDS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIOREDOXIN-DISULFIDE REDUCTASE; THIOREDOXINS; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 84867851103     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.33.201     Document Type: Article

References (43)

1. Acevedo ML and Kraus WL (2003) Mediator and p300/CBPsteroid receptor coactivator complexes have distinct roles, but function synergistically, during estrogen receptor alphadependent transcription with chromatin templates. Mol Cell Biol 23, 335-348.
2. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC and Thomas M (1983) Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 130, 1910-1917.
3. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL and Taylor JR (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276, 1957-1963.
4. Dickson RB and Lippman ME (1987) Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8, 29-43.
5. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, Fischbach LA, Marshall JR and Clark LC (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11, 630-639.
6. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science. 240, 889-895.
7. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR and Katzenellenbogen BS (2003) Profiling of estrogen upand down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144, 4562-4574.
8. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW and Vogelstein B (1997) 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1, 3-11.
9. Hill KE, McCollum GW, Boeglin ME and Burk RF (1997) Thioredoxin reductase activity is decreased by selenium deficiency. Biochem Biophys Res Commun 234, 293-295.
10. Hirabayashi Y and Zhang M (2009) Comparison of time trends in breast cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn J Clin Oncol 39, 411-412
11. Holmgren A and Björnstedt M (1995) Thioredoxin and thioredoxin reductase. Methods Enzymol 252, 199-208.
12. Ikeda K, Orimo A, Higashi Y, Muramatsu M and Inoue S (2000) Efp as a primary estrogen-responsive gene in human breast cancer. FEBS Lett 472, 9-13.
13. Jakacka M, Ito M, Weiss J, Chien PY, Gehm BD and Jameson JL (2001) Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem 276, 13615-13621.
14. Jiang C, Wang Z, Ganther H and Lu J (2001) Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 61, 3062-3070.
15. Key T, Appleby P, Barnes I and Reeves G; The Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 94, 606-616.
16. Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29, 2905-2919.
17. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM and Webb P (2000) Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74, 311-317.
18. Kyprianou N, English HF, Davidson NE and Isaacs JT (1991) Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51, 162-166.
19. Lau KM, Mok SC and Ho SM (1999) Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 96, 5722-5727.
20. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W and Sobue T; Japan Cancer Surveillance Research Group (2012) Cancer incidence and incidence rates in Japan in 2006: Based on data from 15 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 42, 139-147.
21. Medina D, Lane HW and Shepherd F (1983) Effect of dietary selenium levels on 7,12-dimethylbenzanthraceneinduced mouse mammary tumorigenesis. Carcinogenesis 4, 1159-1163.
22. Okoh V, Deoraj A and Roy D (2011) Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer. Biochim Biophys Acta 1815, 115-133.
23. Olea N, Pulgar R, Pérez P, Olea-Serrano F, Rivas A, Novillo-Fertrell A, Pedraza V, Soto AM and Sonnenschein C (1996) Estrogenicity of resin-based composites and sealants used in dentistry. Environ Health Perspect 104, 298-305.
24. Orimo A, Inoue S, Minowa O, Tominaga N, Tomioka Y, Sato M, Kuno J, Hiroi H, Shimizu Y, Suzuki M, Noda T and Muramatsu M (1999) Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor alpha. Proc Natl Acad Sci USA 96, 12027-12032.
25. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ and Scanlan TS (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277, 1508-1510.
26. Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Wärri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M and Gustafsson JA (2002) Estrogen receptor beta in breast cancer. Endocr Relat Cancer 9, 1-13.
27. Perillo B, Sasso A, Abbondanza C and Palumbo G (2000) 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20, 2890-2901.
28. Prall OW, Sarcevic B, Musgrove EA, Watts CK and Sutherland RL (1997) Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272, 10882-10894.
29. Prall OW, Rogan EM, Musgrove EA, Watts CK and Sutherland RL (1998) c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 18, 4499-4508.
30. Qin C, Singh P and Safe S (1999) Transcriptional activation of insulin-like growth factor-binding protein-4 by 17betaestradiol in MCF-7 cells: role of estrogen receptor-Sp1 complexes. Endocrinology 140, 2501-2508.
31. Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, Roe D, Payne CM and Nelson MA (1998) Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 125, 103-110.
32. Sakazaki, H, Ueno H, Umetani K, Utsumi H and Nakamuro K (2001) Immunotoxicological evaluation of environmental chemicals utilizing mouse lymphocyte mitogenesis test. J Health Sci 47, 258-271.
33. Shah YM, Kaul A, Dong Y, Ip C and Rowan BG (2005) Attenuation of estrogen receptor alpha (ERalpha) signaling by selenium in breast cancer cells via downregulation of ERalpha gene expression. Breast Cancer Res Treat 92, 239-250.
34. Shin HR, Boniol M, Joubert C, Hery C, Haukka J, Autier P, Nishino Y, Sobue T, Chen CJ, You SL, Ahn SH, Jung KW, Law SC, Mang O and Chia KS (2010) Secular trends in breast cancer mortality in five East Asian populations: Hong Kong, Japan, Korea, Singapore and Taiwan. Cancer Sci 101, 1241-1246.
35. Sun JM, Chen HY and Davie JR (2001) Effect of estradiol on histone acetylation dynamics in human breast cancer cells. J Biol Chem 276, 49435-49442.
36. Sutherland RL, Prall OW, Watts CK and Musgrove EA (1998) Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia 3, 63-72.
37. Tamir S, Izrael S and Vaya J (2002) The effect of oxidative stress on ERalpha and ERbeta expression. J Steroid Biochem Mol Biol 81, 327-332.
38. Toyo'Oka T and Imai K (1983) High-performance liquid chromatography and fluorometric detection of biologically important thiols, derivatized with ammonium 7-fluorobenzo- 2-oxa-1,3-diazole-4-sulphonate (SBD-F). J Chromatogr 282, 495-500.
39. Tsai MJ and O'Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem, 63, 451-486.
40. Wang TT and Phang JM (1995) Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55, 2487-2489.
41. Weihua Z, Lathe R, Warner M and Gustafsson JA (2002) An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 99, 13589-13594.
42. Yamamoto Y and Takahashi K (1993) Glutathione peroxidase isolated from plasma reduces phospholipid hydroperoxides. Arch Biochem Biophys 305, 541-545.
43. Zhang Y (2001) Molecular mechanism of rapid cellular accumulation of anticarcinogenic isothiocyanates. Carcinogenesis 22, 425-431.